Quince Therapeutics, Inc.

NasdaqGS QNCX

Quince Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 2,090.08

Quince Therapeutics, Inc. Price to Sales Ratio (P/S) is 2,090.08 on January 14, 2025, a 31.23% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Quince Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 2,640.10 on December 03, 2024, which is 26.32% above the current Price to Sales Ratio (P/S).
Quince Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 659.60 on August 15, 2024, which is -68.44% below the current Price to Sales Ratio (P/S).
Quince Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 1,335.91.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: QNCX

Quince Therapeutics, Inc.

CEO	Dr. Dirk Thye M.D.
IPO Date	May 9, 2019
Location	United States
Headquarters	601 Gateway Blvd
Employees	32
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Key trends

Past 5 years